The FDA approves the pill version of Wegovy in the United States, the first oral semaglutide-based drug indicated for weight loss. Clinical studies show similar efficacy to injections, with potential advantages in terms of access and therapeutic adherence.
In the United States the fight against obesity has just marked one of the most significant stages in recent years: the Food and Drug Administration (FDA) ha officially approved the pill version of Wegovythe semaglutide-based slimming drug already available for years in the injectable formulation. It’s the first oral GLP-1 treatment indicated specifically for weight management in adultsand promises to revolutionize treatment access and adherence for millions of people living with obesity or overweight complicated by related medical risk factors. According to the official press release of Novo Nordiskthe Danish pharmaceutical company that produces the medicine, the pill contains 25 mg semaglutidethe active ingredient already known in the injectable versions of Wegovy and in the oral ones for diabetes (Rybelsus), but in a higher dosage to ensure effectiveness in weight loss. The new Wegovy in pill form is indicated for adults with obesity or overweight associated with related medical conditions, such as hypertension, type 2 diabetes or other comorbidities. As with the injectable version, combined use with a is intended low-calorie diet and increased physical activity.
Clinical efficacy: numbers that confirm the benefits
The approval is based on study data OASIS 4a phase 3 clinical trial that compared the effects of the pill taken once a day with a placebo. The results were remarkable: those who followed the treatment with the tablet recorded a average weight loss of approximately 16.6% compared to initial weight after 64 weeks, numbers very similar to those obtained with the injectable version. If we consider the analysis based on all participants regardless of treatment continuity, the average decrease remains significant, with approximately 13.6% weight loss compared to the starting point. In addition to weight loss, the Wegovy pill has also been approved to reduce the risk of major cardiovascular events — such as heart attack or stroke — in adults with obesity and established heart disease, a therapeutic extension of great clinical importance.
Convenience and access: why the pill can change the rules of the game
The news also aroused strong interest due to its practical impact on the healthcare area: Novo Nordisk plans to launch the product in the United States in early January 2026 with a starting dose available at approx $149 a monthsignificantly lower than the average cost of injections. The oral form can result more attractive and comfortable for patientsovercoming barriers such as fear of needles or difficulty managing weekly injections. Experts point out that an oral option is often associated with better therapeutic adherenceespecially in long-term therapies. However, it should be remembered that the pill must be taken on an empty stomachwith a waiting period before eating or drinking, a limitation due to the need to prevent gastric enzymes from reducing the absorption of the active ingredient. Side effects — such as nausea, diarrhea or vomiting — also remain similar to those already known with injectable versions.
Competition and market: the race for anti-obesity pills
The approval of Wegovy in pill form comes at a time of Growing competition in the obesity treatment market. Eli LillyNovo Nordisk’s historic competitor, is in fact carrying on orforglipronanother GLP-1 tablet in advanced regulatory review, with promising data on weight maintenance after switching from injections. The dynamic between these products and the rapid expansion of anti-obesity therapies signals the beginning of a new era of oral drugs which could expand access to millions of people around the world facing obesity and related health conditions, a growing global health challenge.
There Wegovy pill represents one of the most concrete advances in the field of pharmacological management of obesity in recent years: combining effectiveness, practicality and potential economic accessibility, it offers a new therapeutic hope for patients who until now had few satisfactory alternatives to weekly injections. 2026 could be the year obesity management turns a new leaf — with the tablet as the main protagonist.
